Nanobiotix
Develops NBTXR3, radiation-enhancing nanoparticles licensed to Johnson & Johnson as JNJ-1900.
16 of 403 companies
Develops NBTXR3, radiation-enhancing nanoparticles licensed to Johnson & Johnson as JNJ-1900.
Licenses and runs global development of Nanobiotix's NBTXR3 nanoparticle as JNJ-1900.
Supplies lipid nanoparticle delivery systems to partners developing nucleic acid drugs.
Developed cell-targeted lipid nanoparticles for siRNA; agreed to be acquired by XOMA Royalty.
Royalty aggregator that agreed to buy Generation Bio and its ctLNP platform.
Partnered with Calico on aging drug research for over a decade before ending the alliance in 2025.
Develops SORT lipid nanoparticles that deliver mRNA and gene correction to specific tissues.
Built targeted LNPs to make CAR-T cells inside the body; acquired by AbbVie in 2025.
Commercial mRNA company with LUNAR lipid-mediated delivery and self-amplifying mRNA.
Partners with Arcturus on the self-amplifying mRNA vaccine KOSTAIVE.
Formerly Nanotronics; builds AI-driven factories and inspection to scale novel materials.
Funds nanotechnology and molecular manufacturing research through grants and prizes.
Licenses LNP and ligand conjugate platforms for delivering nucleic acid drugs.
Shrinks drug particles to the nanoscale with its CESS process to improve drugs.
Manufactures graphene at industrial scale.
Researches atomically precise manufacturing and nano-imprint lithography.